Low rather than high interleukin-6 levels are associated with immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

在接受免疫检查点抑制剂治疗的癌症患者中，低水平的白细胞介素-6（IL-6）而非高水平的IL-6与免疫相关不良事件有关。